Waiting for a drugmaker's clinical trial results can be one of the toughest aspects of biotech investing. Exelixis'
XL184 is Exelixis' proposed small-molecule pill to treat a form of late-stage thyroid cancer. Although XL184 is not Exelixis' first phase 3 drug candidate -- its bile duct tumor treatment XL119 failed in testing two years ago -- it's now Exelixis' only compound in active phase 3 development.
Anti-cancer drug studies usually take a long time to produce clinical trial results, but a quick look at clinicaltrials.gov shows that Exelixis expects the first phase 3 data from XL184 around next December. If it's positive, the progression-free survival (PFS) data expected then could be enough for Exelixis to have XL184 approved and on the market by late 2010.
At best, this is a rough guess at XL184's timeline; it can be very tough to predict when data from cancer clinical trials will come out. The data may face several months' delay if either the placebo group or XL184-treated patients end up surviving longer than expected. Also, if the PFS data next year is not good, XL184 won't necessarily be dead in development. The study will look at other measures of efficacy, like overall survival, that could still get the drug approved -- albeit at a much later date.
There are currently no targeted therapies on the market specifically approved to treat the form of thyroid cancer that XL184 attacks. Other drugmakers like AstraZeneca
Exelixis is an active pick of our market-beating Rule Breakers newsletter service. Check out all our other recommendations, and get access to our message boards and exclusive content, with a 30-day free trial.
Fool contributor Brian Lawler does not own shares of any company mentioned in this article. Pfizer is an Inside Value pick. Pfizer and Glaxo are Income Investor picks. The Motley Fool owns shares of Exelixis. The Fool has a very patient disclosure policy.